Aaron Royston, Director at Akero Therapeutics, Inc. (AKRO), bought 485,099 shares at $16.00 ($4.0M) on 2019-06-24, disclosed to the SEC on 2019-06-25.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 235,099 | $0 | 0.0% |
| 2 | $16.00 | 250,000 | $4.0M | 100.0% |
| Total | $8.25 avg | 485,099 | $4.0M | 100% |
| Filing → |